Entry |
|
Name |
Ulcerative colitis |
Supergrp |
Inflammatory bowel disease (IBD) [DS: H01227] |
Description |
Ulcerative colitis (UC) is one subtype of inflammatory bowel disease (IBD) whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. In UC the inflammatory is limited to the musoca of the colon and rectum. Clinically, the most common manifestation of UC may include bloody diarrhea, abdominal pain. In most severe cases, patients may experience fever, weight loss, anemia, and the intestine can get distended, presenting deep ulceration and possibly intestinal perforation.The long-time duration of the disease increases a colorectal caner risk. UC is associated with a Th2 immune response. Recent genetic analyses have linked genes including interleukin 23 receptor, interleukin 10 and macrophage stimulating 1.
|
Category |
Immune system disease
|
Brite |
Human diseases [BR:br08402]
Immune system diseases
Other immune system diseases
H01466 Ulcerative colitis
Human diseases in ICD-11 classification [BR:br08403]
13 Diseases of the digestive system
Inflammatory bowel diseases
DD71 Ulcerative colitis
H01466 Ulcerative colitis
|
Pathway |
hsa04060 Cytokine-cytokine receptor interaction | |
|
Gene |
|
Pathogen |
Fusobacterium varium [GN: fva] |
Drug |
Triamcinolone acetonide [DR: D00983]
Dexamethasone [DR: D00292]
Dexamethasone sodium phosphate [DR: D00975]
Hydrocortisone [DR: D00088]
Hydrocortisone acetate [DR: D00165]
Hydrocortisone sodium succinate [DR: D00978]
Prednisolone [DR: D00472]
Prednisolone sodium phosphate [DR: D00981]
Prednisone [DR: D00473]
Budesonide [DR: D00246]
Sulfasalazine [DR: D00448]
Mesalamine [DR: D00377]
Olsalazine sodium [DR: D00727]
Balsalazide disodium [DR: D02715]
Methylprednisolone [DR: D00407]
Methylprednisolone sodium succinate [DR: D00751]
Methylprednisolone acetate [DR: D00979]
Cortisone acetate [DR: D00973]
Vedolizumab [DR: D08083]
Infliximab [DR: D02598]
Adalimumab [DR: D02597]
Golimumab [DR: D04358]
|
Other DBs |
|
Reference |
|
Authors |
de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU |
Title |
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. |
Journal |
|
Reference |
|
Authors |
Abraham C, Cho JH |
Title |
Inflammatory bowel disease. |
Journal |
|
Reference |
|
Authors |
Pang YH, Zheng CQ, Yang XZ, Zhang WJ |
Title |
Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients. |
Journal |
|
Reference |
|
Authors |
Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S |
Title |
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. |
Journal |
|
Reference |
|
Authors |
Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H |
Title |
Promising biological therapies for ulcerative colitis: A review of the literature. |
Journal |
|
Reference |
|
Authors |
Danese S, Vuitton L, Peyrin-Biroulet L |
Title |
Biologic agents for IBD: practical insights. |
Journal |
|
LinkDB |
|